Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q2 2024
Top Holdings41 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
UNITED THERAPEUTICS CORP | 2.9M | $910.7M | 12.1% | $151.50 | +110.26% | 15 qtrssince 2020-Q4 | Unchanged 0 |
MADRIGAL PHARMACEUTICALS INC | 2.1M | $575.9M | 7.7% | $157.20 | +78.22% | 22 qtrssince 2019-Q1 | Increased 66 |
ASCENDIS PHARMA A/S | 4.2M | $572.3M | 7.6% | $123.77 | +10.19% | 13 qtrssince 2021-Q2 | Increased 66 |
ARGENX SE - ADR | 1.2M | $532.6M | 7.1% | $224.78 | +91.32% | 22 qtrssince 2019-Q1 | Unchanged 0 |
AVI BIOPHARMA INC | 3M | $474M | 6.3% | $107.06 | +47.58% | 22 qtrssince 2019-Q1 | Decreased 0 |
Krystal Biotech, Inc. | 2.4M | $446.8M | 6.0% | $85.59 | +114.55% | 11 qtrssince 2021-Q4 | Decreased 0 |
APELLIS PHARMACEUTICALS INC | 11.1M | $426.2M | 5.7% | $43.88 | -12.58% | 14 qtrssince 2021-Q1 | Unchanged 0 |
BIOMARIN PHARMACEUTICAL INC | 4.6M | $375.2M | 5.0% | $86.88 | -5.24% | 22 qtrssince 2019-Q1 | Increased 61 |
CEREVEL THERAPEUTICS HLDNG I | 7.5M | $308.3M | 4.1% | — | — | 4 qtrssince 2023-Q3 | Decreased 0 |
SPDR S&P BIOTECH ETF | 3M | $281.4M | 3.7% | $88.83 | +3.96% | 3 qtrssince 2023-Q4 | Decreased 0 |
AMICUS THERAPEUTICS INC | 27.4M | $271.8M | 3.6% | $11.07 | -10.38% | 22 qtrssince 2019-Q1 | Unchanged 0 |
| 6.5M | $265.7M | 3.5% | $25.80 | +58.33% | 17 qtrssince 2020-Q2 | Increased 64 | |
ARROWHEAD PHARMACEUTICALS IN | 8.9M | $231M | 3.1% | $28.88 | -10.02% | 5 qtrssince 2023-Q2 | Increased 60 |
XENON PHARMACEUTICALS INC | 5.7M | $220.9M | 2.9% | $21.21 | +83.80% | 22 qtrssince 2019-Q1 | Unchanged 0 |
INTRA-CELLULAR THERAPIES INC | 3M | $205.5M | 2.7% | — | — | 3 qtrssince 2023-Q4 | Increased 64 |
VERA THERAPEUTICS INC | 4.3M | $155.9M | 2.1% | $43.12 | -16.09% | 2 qtrssince 2024-Q1 | Decreased 0 |
MoonLake Immunotherapeutics Class A | 2.8M | $121.8M | 1.6% | $53.13 | -17.24% | 5 qtrssince 2023-Q2 | Increased 52 |
KYMERA THERAPEUTICS INC | 3.9M | $116.1M | 1.5% | $30.08 | -0.78% | 12 qtrssince 2021-Q3 | Unchanged 0 |
ALNYLAM PHARMACEUTICALS INC | 400,000 | $97.2M | 1.3% | $186.77 | +20.25% | 13 qtrssince 2021-Q2 | Increased 61 |
IOVANCE BIOTHERAPEUTICS INC | 11.7M | $93.8M | 1.2% | $15.03 | -46.64% | 22 qtrssince 2019-Q1 | Unchanged 0 |
Avoro Capital Advisors LLC manages $7.5B across 41 positions as of Q2 2024. Top holdings: UTHR (12.1%), MDGL (7.7%), ASND (7.6%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.
Active quarter - 3 new positions, 8 exits, 11 increased. Top move: MDGL (INCREASED, conviction 66). Portfolio: $7.5B across 41 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer